ATE210649T1 - Arylacrylamidderivate als 5ht1 agoniste oder antagoniste - Google Patents

Arylacrylamidderivate als 5ht1 agoniste oder antagoniste

Info

Publication number
ATE210649T1
ATE210649T1 AT97302995T AT97302995T ATE210649T1 AT E210649 T1 ATE210649 T1 AT E210649T1 AT 97302995 T AT97302995 T AT 97302995T AT 97302995 T AT97302995 T AT 97302995T AT E210649 T1 ATE210649 T1 AT E210649T1
Authority
AT
Austria
Prior art keywords
agonists
antagonists
arylacrylamide
derivatives
arylacrylamide derivatives
Prior art date
Application number
AT97302995T
Other languages
English (en)
Inventor
Harry Ralph Howard
Barbara Eileen Segelstein
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE210649T1 publication Critical patent/ATE210649T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97302995T 1996-05-28 1997-05-01 Arylacrylamidderivate als 5ht1 agoniste oder antagoniste ATE210649T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1858096P 1996-05-28 1996-05-28

Publications (1)

Publication Number Publication Date
ATE210649T1 true ATE210649T1 (de) 2001-12-15

Family

ID=21788674

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97302995T ATE210649T1 (de) 1996-05-28 1997-05-01 Arylacrylamidderivate als 5ht1 agoniste oder antagoniste

Country Status (9)

Country Link
US (1) US6258953B1 (de)
EP (1) EP0810220B1 (de)
JP (1) JP3026948B2 (de)
AT (1) ATE210649T1 (de)
CA (1) CA2206122C (de)
DE (1) DE69708968T2 (de)
DK (1) DK0810220T3 (de)
ES (1) ES2166046T3 (de)
PT (1) PT810220E (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
PT952154E (pt) 1998-04-16 2004-12-31 Pfizer Prod Inc N-acil- e n-aroil-aralquilamidas
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
PE20000942A1 (es) * 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
EP1392644A1 (de) 2001-05-31 2004-03-03 Bristol-Myers Squibb Company Cinnamidderivate als kcnq kaliumkanalmodulatoren
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
AU2003295782A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
US7135472B2 (en) 2002-11-22 2006-11-14 Bristol-Myers Squibb Company 3-Heterocyclic benzylamide derivatives as potassium channel openers
EP1572112A4 (de) 2002-11-22 2006-12-06 Bristol Myers Squibb Co 3-(pyridinyl-piperazin-1-yl)-phenylethylamide alskaliumkanalöffner
AU2003294441A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
US7144881B2 (en) 2002-11-22 2006-12-05 Bristol-Myers Squibb Company Arylcyclopropylcarboxylic amides as potassium channel openers
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
EP1737466A1 (de) * 2004-01-29 2007-01-03 Pfizer Products Inc. KOMBINATION VON Y-AMINOBUTTERSÄURE-MODULATOREN UND 5HT-1b REZEPTOR-ANTAGONISTEN
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
CN102515996B (zh) * 2011-11-14 2015-11-25 南开大学 一种合成β-芳基丙烯酰胺类化合物的方法
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US11135207B2 (en) 2016-12-13 2021-10-05 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4564685A (en) * 1983-03-10 1986-01-14 Findlay John W A Diphenylmethane compounds
CA2158457C (en) * 1993-03-16 2001-04-17 Bertrand Leo Chenard Naphthalene derivatives

Also Published As

Publication number Publication date
CA2206122C (en) 2002-03-05
EP0810220A1 (de) 1997-12-03
MX9703899A (es) 1998-06-30
DK0810220T3 (da) 2002-03-18
DE69708968D1 (de) 2002-01-24
JPH1095765A (ja) 1998-04-14
JP3026948B2 (ja) 2000-03-27
EP0810220B1 (de) 2001-12-12
US6258953B1 (en) 2001-07-10
PT810220E (pt) 2002-04-29
ES2166046T3 (es) 2002-04-01
CA2206122A1 (en) 1997-11-28
DE69708968T2 (de) 2002-04-25

Similar Documents

Publication Publication Date Title
ATE210649T1 (de) Arylacrylamidderivate als 5ht1 agoniste oder antagoniste
DE69628804D1 (de) Substitutierte heterozyclische Derivate als CRF Antagonisten
ID18883A (id) Pesaing 5-ht 1f
DK0957099T3 (da) Heterocykliske carboxamider
DE69319976D1 (de) 7-Substituierte-9-substituierte Glycylamido-6-Demethyl-6-Deoxytetracycline
PT931788E (pt) Inibidores de metaloprotease
DE69129009D1 (de) Indole Derivate als Serotonin-Antagonisten
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
FI902555A0 (fi) Diarylstyrylkinolindisyror.
DE60121461D1 (de) Kondensierte pyridoindolderivate
ID23053A (id) Karboksamida yang digunakan sebagai agonis 5-ht <if>
ATE177096T1 (de) 4-substituierte 1,2,4-triazolderivate
PT952154E (pt) N-acil- e n-aroil-aralquilamidas
FI900041A0 (fi) Substituerade indol-, benzofuran- och benzotiopenderivat saosom 5-lipoxigenasinhibitorer,
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
DE60112960D1 (de) Kondensierte pyridoindolderivate
DK0767782T3 (da) Aryl- og heteroarylalkoxynaphthalenderivater
ITMI930819A1 (it) Derivati eterobiciclici ad attivita' fungicida
PT1140932E (pt) Derivados de 1,8-benzonaftiridina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee